Evaluation of the safety of using propofol for paediatric procedural sedation: A systematic review and meta-analysis

Sunhee Kim, Seokyung Hahn, Myoung jin Jang, Yunhee Choi, Hyunsook Hong, Ji Hyun Lee, Hee Soo Kim

Research output: Contribution to journalArticle

Abstract

Propofol is one of the most widely used drugs for paediatric procedural sedation owing to its known advantages, but some concerns remain regarding respiratory and/or cardiac complications in patients receiving propofol. Although a considerable number of randomised controlled clinical trials (RCTs) have been conducted to compare it with other sedative agents or opioids for children undergoing various procedures, propofol is still being used off-label for this indication in many countries. We performed a systematic review and meta-analysis of those RCTs to provide an overall summation of evidence that can potentially be considered for further regulatory decisions, including reimbursement policies. We searched for RCTs in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception to January 31, 2018. Our meta-analysis of 30 RCTs confirmed that propofol sedation had advantages in recovery time when compared with other drugs, without excessive concerns for cardiovascular or respiratory adverse events. Its safety profile regarding coughing, nausea or vomiting, and emergence delirium was also similar to that of other drugs. The overall evidence suggests that propofol sedation for paediatric procedures should be considered more positively in the context of regulatory decisions.

Original languageEnglish
Article number12245
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2019

Fingerprint

Propofol
Meta-Analysis
Pediatrics
Safety
Randomized Controlled Trials
Pharmaceutical Preparations
Hypnotics and Sedatives
MEDLINE
Nausea
Opioid Analgesics
Vomiting

Cite this

@article{90ab40f136a540f1a5fdb46edef0172b,
title = "Evaluation of the safety of using propofol for paediatric procedural sedation: A systematic review and meta-analysis",
abstract = "Propofol is one of the most widely used drugs for paediatric procedural sedation owing to its known advantages, but some concerns remain regarding respiratory and/or cardiac complications in patients receiving propofol. Although a considerable number of randomised controlled clinical trials (RCTs) have been conducted to compare it with other sedative agents or opioids for children undergoing various procedures, propofol is still being used off-label for this indication in many countries. We performed a systematic review and meta-analysis of those RCTs to provide an overall summation of evidence that can potentially be considered for further regulatory decisions, including reimbursement policies. We searched for RCTs in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception to January 31, 2018. Our meta-analysis of 30 RCTs confirmed that propofol sedation had advantages in recovery time when compared with other drugs, without excessive concerns for cardiovascular or respiratory adverse events. Its safety profile regarding coughing, nausea or vomiting, and emergence delirium was also similar to that of other drugs. The overall evidence suggests that propofol sedation for paediatric procedures should be considered more positively in the context of regulatory decisions.",
author = "Sunhee Kim and Seokyung Hahn and Jang, {Myoung jin} and Yunhee Choi and Hyunsook Hong and Lee, {Ji Hyun} and Kim, {Hee Soo}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-48724-x",
language = "English",
volume = "9",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Evaluation of the safety of using propofol for paediatric procedural sedation : A systematic review and meta-analysis. / Kim, Sunhee; Hahn, Seokyung; Jang, Myoung jin; Choi, Yunhee; Hong, Hyunsook; Lee, Ji Hyun; Kim, Hee Soo.

In: Scientific Reports, Vol. 9, No. 1, 12245, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the safety of using propofol for paediatric procedural sedation

T2 - A systematic review and meta-analysis

AU - Kim, Sunhee

AU - Hahn, Seokyung

AU - Jang, Myoung jin

AU - Choi, Yunhee

AU - Hong, Hyunsook

AU - Lee, Ji Hyun

AU - Kim, Hee Soo

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Propofol is one of the most widely used drugs for paediatric procedural sedation owing to its known advantages, but some concerns remain regarding respiratory and/or cardiac complications in patients receiving propofol. Although a considerable number of randomised controlled clinical trials (RCTs) have been conducted to compare it with other sedative agents or opioids for children undergoing various procedures, propofol is still being used off-label for this indication in many countries. We performed a systematic review and meta-analysis of those RCTs to provide an overall summation of evidence that can potentially be considered for further regulatory decisions, including reimbursement policies. We searched for RCTs in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception to January 31, 2018. Our meta-analysis of 30 RCTs confirmed that propofol sedation had advantages in recovery time when compared with other drugs, without excessive concerns for cardiovascular or respiratory adverse events. Its safety profile regarding coughing, nausea or vomiting, and emergence delirium was also similar to that of other drugs. The overall evidence suggests that propofol sedation for paediatric procedures should be considered more positively in the context of regulatory decisions.

AB - Propofol is one of the most widely used drugs for paediatric procedural sedation owing to its known advantages, but some concerns remain regarding respiratory and/or cardiac complications in patients receiving propofol. Although a considerable number of randomised controlled clinical trials (RCTs) have been conducted to compare it with other sedative agents or opioids for children undergoing various procedures, propofol is still being used off-label for this indication in many countries. We performed a systematic review and meta-analysis of those RCTs to provide an overall summation of evidence that can potentially be considered for further regulatory decisions, including reimbursement policies. We searched for RCTs in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception to January 31, 2018. Our meta-analysis of 30 RCTs confirmed that propofol sedation had advantages in recovery time when compared with other drugs, without excessive concerns for cardiovascular or respiratory adverse events. Its safety profile regarding coughing, nausea or vomiting, and emergence delirium was also similar to that of other drugs. The overall evidence suggests that propofol sedation for paediatric procedures should be considered more positively in the context of regulatory decisions.

UR - http://www.scopus.com/inward/record.url?scp=85071160674&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-48724-x

DO - 10.1038/s41598-019-48724-x

M3 - Article

C2 - 31439875

AN - SCOPUS:85071160674

VL - 9

JO - Scientific reports

JF - Scientific reports

SN - 2045-2322

IS - 1

M1 - 12245

ER -